Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B

Data shows deep repression of HBV both in primary cells and ‘gold standard’ humanized mouse model Therapeutic targets a single “master controller” sequence to silence all forms of the virus Approach offers a path to functional cure for HBV DURHAM, NC and SEATTLE, WA (December 5, 2023) – Leading epigenome editing company Tune Therapeutics presented data in support […]